Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pharmaceuticals Année : 2021

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

Résumé

The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection. Forty-nine FIASMAs have been suggested in the treatment of SARS-CoV-2 infection using in silico, in vitro or in vivo studies. Further studies using large-sized, randomized and double-blinded controlled clinical trials are needed to evaluate FIASMAs in SARS-CoV-2 infection as off-label therapy.
Fichier principal
Vignette du fichier
doi_314960.pdf (369.72 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03341352 , version 1 (10-09-2021)

Licence

Paternité

Identifiants

Citer

Gwenole Loas, Pascal Le Corre. Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals, 2021, 14 (7), pp.691. ⟨10.3390/ph14070691⟩. ⟨hal-03341352⟩
35 Consultations
114 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More